Index

Page numbers in *italics* refer to Figures; those in **bold** to Tables

absent end-diastolic flow (AEDF), 346, 348, 350
acquired immunodeficiency syndrome (AIDS), 239
acupressure, 301
acute abdominal pain
diagnosis and treatment, **262, 262–4**
laboratory and imaging evaluation, **264, 264–5**
pathophysiology, 260–261, **261**
treatment, 265
acute appendicitis, 265
adnexal torsion, 266
cholecytitis/choledolithiasis, 266
hepatitis, 267
intraabdominal hemorrhage, 268
laboratory and imaging evaluation, **264, 264–5**
ovarian cysts, 266
pancreatitis, 267
pelvic inflammatory disease, 268
urinary calculi, 267
urinary tract infection, 266
uterine leiomyomata, 267
acute appendicitis, 265
acute fatty liver of pregnancy (AFLP), **277**
clinical significance, **270, 271**
complications, 276
diagnosis, 273
pathophysiology, 272
treatment, 275
Advanced Cardiac Life Support, 407
AEDF see absent end-diastolic flow (AEDF)
AFE see amniotic fluid embolism (AFE)
AFI see amniotic fluid index (AFI)
AFLP see acute fatty liver of pregnancy (AFLP)
alcohol abuse
clinical significance, 7–8
risk drinking, treatment of, 8–9
screening, 8
alloimmunizations
first pregnancy, 355–7, 356, 357
outcome and follow up, 359
pathophysiology, 353, 355
prevention, 359–61, **361**
subsequent pregnancy, 357–8
management, 358–9
amnionitis
clinical presentation, 393–4
complications, 396
diagnosis and management, 394–5, **395**
pathophysiology, 392–3
prevention, 396
risk factors, 393
treatment, 395–6
amniotic fluid (AF), 75, 343
fetal platelet typing, 73
GBS, 253
nicotine, 4
amniotic fluid embolism (AFE)
management, 407
pathophysiology, 406
amniotic fluid index (AFI), 66, 68, 318, 318, 319, 343, 380
amniotic fluid volume
fluid production, 316–17
fluid removal, 317
gestational age, 317
oligohydramnios, 315
AFI, 318, 318
amnioinfusion, 322–3
during delivery, 322
diagnosis, 317–19, **320**
evaluation, 319–21
fetal growth and placental function, 321
fetal urine tract anatomy and function, 321
maternal hydration, 323
pulmonary hypoplasia, 321–2
perinatal morbidity, **315**
polyhydramnios
amniocentesis, 325
amnioreduction, 326–7
biophysical monitoring, 327
clinical associations, **324**
complications, 325
diagnosis, 324–5
indomethacin, 327
laboratory screening, 325
labor management, 326
pathological accumulation, 323
preterm labor, cervical length for, 326
sonography, 325
treatment options, 326
amniotomy, 415
aneuploidy, 39, 41, 283, 343, 454
antepartum testing
antepartum fetal surveillance, 69
biophysical profile, 66–7, 67
contraction stress test, 68–9
indication, 70
modified biophysical profile, 67–8
nonstress test, 65–6
anticoagulation therapy, 117, 148
antihypertensive therapy
chronic hypertension, 204, 207, 209–10
preeclampsia, 332
scleroderma, 113
superimposed preeclampsia, 204
antiphospholipid antibody syndrome, 148, 329
anticoagulation therapy, 117
diagnosis, 116
effect on pregnancy, 116
pathophysiology, 115–16
postpartum, 118
pregnancy monitoring, 117
timing of delivery, 117
antithyroid peroxidase antibodies (TPO), 173
arterosina-based combination therapy (ACT), 235–6
arthralgias, 104, 247, 248
asthma
diagnosis, 188–9
follow-up, 194–5
management, 189–90
of acute asthma, 193–4, 194
of chronic asthma, 190–193, 191–3
pathophysiology, 188
autoimmune disease
rheumatoid arthritis, 110–111
scleroderma, 112–13
systemic lupus erythematosus, 104–10
B19 infection
biophysical profile (BPP), 66–7, 67, 154, 377
biparietal diameter (BPD), 342, 445
Bishop score, 311, 412, 413
bleeding 4th third trimester bleeding
blood transfusion, 62, 87, 91
“brain-sparing” effect, 346
breastfeeding, 111, 238, 242
breech presentation
delivery, 424–6
diagnosis, 423
external cephalic version, 423
PROM, 371
carbon monoxide, 4
cardiac abnormalities, 56, 58
cardiac disease
antepartum and postpartum care, 128
anticoagulation
anesthesia, 135–6
prophylactic antibiotics, 135, 135
vaginal and cesarean delivery, 136
vascular disruption, 134
warfarin, 133
diagnosis and workup, 130, 132–3
maternal mortality, 128
pathophysiology, 128–32, 131–2, 132
patient follow up, 137
principles, 133
cerebral palsy
clinical significance, 388
complications, 390–391
diagnosis, 388–9
pathophysiology, 388
prevention, 389–90, 390
cerclage
abdominal technique, 293
avoiding, 292
emergent, 291–2
McDonald cerclage, 293
preeclampsia, 332
prophylactic, 290–291
removal, 293–4
rescue/urgent, 290–292
Shirodkar cerclage, 293
cerebral palsy
clinical significance, 388
complications, 390–391
diagnosis, 388–9
pathophysiology, 388
prevention, 389–90, 390
cervical insufficiency
adjunctive therapies, 293–4
cerclage see cerclage
diagnosis
clinical, 288–9
physical examination, 289–90
sonography, 290
cervical ripening agents
mechanical agents
intracervical balloon catheter placement, 413–4
membrane stripping, 413
pharmacological agents
fetal surveillance after prostaglandin use, 415
prostaglandin E1, 414
prostaglandin E2, 415
chemical exposures
hairstylists, 10
inhalational anesthetics, 11
painters and artists, 10
pesticide workers, 11
solvent workers, 11
chorioamnionitis
cervical insufficiency, 289
fetal inflammatory response, 421
postpartum hemorrhage, 463
preterm PROM, 370, 371
chromosome aberrations, 473
chronic hypertension
definition, 203
Index 485

diagnosis, 203–4
etiology and classification, 204, 205
maternal–perinatal risks, 204–6, 206
prevalence of, 203

treatment
antihypertensive therapy, 207
evaluation and classification, 207–8
high-risk hypertension, 208–11, 209, 210
low-risk hypertension, 208, 209
suggested management, 207

CMV see cytomegalovirus (CMV)
congenital heart disease (CHD) see also fetal echocardiography
congenital malformations, 478–9
cord prolapse, 371
crown-rump length (CRL), 342
cytomegalovirus (CMV), 213
diagnosis, 214
management, 214
postnatal infection, 214
depression
clinical significance, 27
diagnosis, 28
management, 28–9
pathophysiology, 28
patient follow up, 30
diabetes mellitus
gestational diabetes
antepartum management, 169–70
consequences, 167
definition, 167
delivery, 170
postpartum care, 170–71, 171
screening and diagnosis, 167–9, 168
pathophysiology, 163–4
pregestational diabetes mellitus
antepartum care, 164–5
contraception for, 166
delivery, 165–6, 166
fetal evaluation, 165
malformations, detection and evaluation of, 164
prepregnancy care, 164
risk assessment, 164

Doppler ultrasound
congenital heart disease and arrhythmia, 60
diagnosis
adverse pregnancy events, 58
cardiac flow velocities, 58
Doppler techniques and measurements, 56–7, 57
intrauterine growth restriction, 58–9
Rh sensitization, 59–60
fetal anemia, 61–2
intrauterine growth restriction, 60–1
pathophysiology
cardiac abnormalities, 56

fetal anemia, 55–6
intrauterine growth restriction, 55
normal fetal circulation, 54–5
preterm labor, 56, 62

Down syndrome, 35, 38, 62–3
endoscopic retrograde cholangiopancreatography (ERCP), 256, 275
environmental hazards
chemical exposures
hairdressers, 10
inhaled anaesthetics, 11
painters and artists, 10
pesticide workers, 11
solvent workers, 11
occupational hazards, 11–12
physical agents, 9–10
enzyme-linked immunosorbent assay (ELISA), 226, 239, 246
epilepsy
anticonvulsant drugs, teratogenicity of, 197–8
breast feeding, 198
first seizure during pregnancy, 201
management, 198–200
pathophysiology, 196–7
postpartum, 201–2
serum levels, 198
treatment
antenatal, 200–201, 201
preconceptional, 200
erlythema infectiosum (EI) see parvovirus B19 infection
erthromycin, 254, 258, 376
erythropoietin, 86–7, 155
estimated fetal weight (EFW), 75, 76, 334, 342, 425, 456
estrogen, 110, 271
ethylene glycol, 11

fatty liver see acute fatty liver of pregnancy (AFLP)

erythrocyte blood sampling (FBS) see fetal blood sampling (FBS)
fetal alcohol syndrome, 7
fetal anemia, 61–2
fetal arrhythmias
diagnosis and management, 51–2
patient follow up, 52
fetal blood sampling (FBS). 481
clinical significance, 71
coagulopathies, 72
complications, 76
congenital infection, 72
cytogenetic diagnosis, 71–2
fetal anemia, 72
fetal growth restriction, 73–4
fetal thyroid dysfunction, 74
platelet disorders, 73
technique, 74–5
transfusion, 75–6
Index

fetal chromosome abnormality
  diagnosis and screening protocols
    first trimester combined screening, 37
    invasive prenatal diagnosis, 36–7
    NT sonography see nuchal translucency
NT sonography (NT) sonography
pathophysiology, 35–6

fetal death and stillbirth
  diagnosis, 307
  diagnostic evaluation, 313–14
  dilation and curettage, 309–10
  expectant management, 308
  fetal demise, 310–12
  gestation, 306
  pathophysiology and etiology, 306–7
  patient follow up, 313–14
  treatment, 307–8

fetal echocardiography
  fetal arrhythmias
    diagnosis and management, 51–2
    patient follow up, 52
    pathophysiology, 48
  structural heart disease
    diagnosis and workup, 49, 49–50
    management, 51

fetal growth restriction
  clinical significance, 340
  complications, 344
  counseling, 351
  definition, 340
  diagnosis, 341–3
  management, 347–50, 349
  pathophysiology, 340–341, 341
  surveillance, 344–7
  treatment, 343–4

fetal heart rate (FHR) see intrapartum fetal heart rate monitoring
fifth disease, 247–8
folate deficiency, 83
Food and Drug Administration, 100, 136, 220, 415, 479

GBS see group B streptococcus (GBS)
GDM see gestational diabetes mellitus (GDM)
genital herpes simplex virus
  diagnosis, 215
  management
    antepartum, 215–16
    intrapartum, 216

hemolytic disease of the fetus/newborn (HDFN)
  pathophysiology, 353, 355
  treatment, 358

hepatitis, 267
  clinical manifestations, 181
  clinical significance, 180–181
  complications, 184–5
  diagnosis, 182, 182–3
  features of, 186, 187
  follow up, 185
  pathophysiology, 181–2
  prevention, 185–6
  treatment, 183–4

hepatitis A
  causes, 180
  clinical manifestations, 181
  complications, 184
  diagnosis, 182

Hashimoto thyroiditis, 173
Havrix®, 185
Helicobacter pylori, 299
hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome, 335–6
  complications, 338
  management
    intrapartum, 336–7, 337
    postpartum, 337–8
hemolytic disease
  irregular antibodies, 480
  non-RhD antibodies, 354
  RhD antigen, sensitization, 353

hepatitis, 267
  clinical manifestations, 181
  clinical significance, 180–181
  complications, 184–5
  diagnosis, 182, 182–3
  features of, 186, 187
  follow up, 185
  pathophysiology, 181–2
  prevention, 185–6
  treatment, 183–4

hepatitis A
  causes, 180
  clinical manifestations, 181
  complications, 184
  diagnosis, 182
Index 487

epidemiology, 180
features of, 187
pathophysiology, 181
prevention, 185–6
treatment, 183
hepatitis B
causes, 180
complications, 184
diagnosis, 182, 182
epidemiology, 180
features of, 187
follow up, 185
pathophysiology, 181
prevention, 186
treatment, 183
hepatitis C
causes, 180
complications, 184–5
diagnosis, 182–3
epidemiology, 180
features of, 187
follow up, 185
pathophysiology, 181
prevention, 186
treatment, 183–4
hepatitis D
complications, 185
diagnosis, 183
epidemiology, 180–181
features of, 187
pathophysiology, 181
prevention, 186
treatment, 184
hepatitis E
complications, 185
diagnosis, 183
epidemiology, 181
features of, 187
pathophysiology, 182
prevention, 186
treatment, 184
herpes simplex virus (HSV)
diagnosis, 215
management
antepartum, 215–16
intrapartum, 216
PROM, 380
human immunodeficiency virus (HIV)
clinical significance, 238
diagnosis, 239–41, 240
follow up, 241–2
intrapartum management, 242
malaria, 232
pathophysiology, 238–9
postpartum management, 242
prevention, 243
treatment, 241
Hyperglycemia and Adverse Pregnancy
Outcome (HAPO), 169
hypertension and preeclampsia
hypothyroidism
etiologies, 175
implications for, 175–6
management
antithyroid therapy, 176–7
fetal surveillance, 177–8
pharmacotherapy, 176
subclinical hyperthyroidism, 176
thyroid storm, 178
hypothyroidism
Hashimoto thyroiditis, 173
implications for, 174
iodine deficiency, 174
treatment, 174–5
hypothyroxinemia, 173, 174
induction of labor
Bishop score, 412, 413
mechanical agents, 413–14
pharmacological agents, 414–15
failed induction, 411
patient selection, 411, 412
procedures and agents
amniotomy, 415
oxytocin, 416, 416
risk of, 411
influenza
complications, 224
diagnosis, 223
pathophysiology, 222–3
prevention, 224
treatment, 223–4
inherited thrombophilias
evaluation and treatment
anticoagulation protocols, 125
clinical phenotype, 123
fetal surveillance, 126
low-dose aspirin, 126
prophylactic/low-dose anticoagulation, 124
protein levels, 123
clinical risk factors, 120–122, 121
hemostasis, 119–20
mechanisms, 120
pregnancy outcome, 122–3
interferon-gamma release assays (IGRAs), 228–9
intermittent asthma, 189, 190
intraabdominal hemorrhage, 268
intrapartum antibiotic prophylaxis (IPAP), 252, 253, 254, 258
intrapartum fetal heart rate monitoring
fetal inflammatory response, maternal infection, 421
medical-legal implications, 421–2
pattern interpretation
categories, 420–421
early deceleration, 419
FHR accelerations, 419
late deceleration, 420
prolonged deceleration, 420
intrapartum fetal heart rate monitoring (continued)
variable deceleration, 419–20
rationale for, 418–19
intrauterine growth restriction (IUGR) see fetal growth restriction
intravenous (IV) iron, 87
iodine deficiency, 174
ionizing radiation
carcinogenic effects
childhood leukemia, 21
cohort studies, 23
lethal cancers, 23
imaging examinations, 14
patient evaluation, 21
pregnancy patient status, 25–6
risk factor
doubling dose, 15
embryo, 19–20
evaluation, 16–19
genetic risk, 15
human germ-cell mutation, 14
reproductive and developmental risks, 15–16
iron deficiency
oral preparations for, 86
prophylaxis, 85
treatment of, 85–7
isoimmune thrombocytopenia
antepartum management, 99–101
diagnosis, 98–9
intrapartum management, 101–2
pathophysiology, 97–8
karyotypic abnormalities, 61, 472
labor and delivery
epidural anesthesia, 148
induction of labor
Bishop score, 412, 413
cervical ripening agents, 413–14
patient selection, 411, 412
management of, 431
latent tuberculosis infection (LTI), 228, 229, 230
major congenital malformations (MCMs), 197–8
malaria
clinical features, 233–4
clinical significance, 232–3
complications, 236
diagnosis, 234–5
pathophysiology, 233
prevention, 236–7
treatment, 235, 235–6
malformation, 474–5
maternal anemia
consequences, 81–2
definition, 81
diagnostic workup and treatment, 82
iron deficiency
oral preparations for, 86
prophylaxis, 85
treatment of, 85–7
laboratory values in, 82
macrocytic anemia, 82–3, 83
microcytic anemia, 84, 84–5
normocytic anemia, 83–4, 84
McDonald cerclage, 292
mean gestational sac diameter (MSD), 342
measles, mumps, and rubella (MMR), 217
methimazole (MMI), 176, 177
middle cerebral artery (MCA), 346, 357, 471
mild hypertension, 332–4
multiple gestations
antepartum, management
antepartum testing, 455–6
diabetes screening, 455
early ultrasonography, 453
fetal growth assessment, 455
medications and nutritional requirements, 453
pregnatal diagnosis, 454
preterm birth prevention, 455
cchorionicity determination, 453
cclinical significance, 451
diagnosis, 452–3
electronic fetal monitoring, 457
mode of delivery, 456, 456–7
monoamniotic pregnancies, 457
multifetal pregnancies, 458, 459
pathophysiology, 451–2
placentaion, 452
prevention, 459
selective termination, 459–60
single fetal demise, 458–9
timing of delivery, 456	
twin–twin transfusion, 457–8
mycoplasma, 373
nausea and vomiting during pregnancy (NVP)
cclinical significance, 298
complications, 302–4
diagnosis
differential diagnosis, 300
initial laboratory tests, 300, 301
scoring systems, 300
pathophysiology, 298–9
prevention, 304
 treatment, 301–2, 302, 303
neural tube defect (NTD)
malformation, 474–5
maternal anemia
consequences, 81–2
definition, 81
diagnostic workup and treatment, 82
Index 489

fetal growth, assessment of, 61
fetal surveillance, 107
NTD see neural tube defect (NTD)
nuchal translucency, 467, 470
nuchal translucency (NT) sonography
AFP, hCG, uE3, and inhibin-A, 44
components, 38
first and second trimester screening, 44–5
noninvasive prenatal testing, 45–6
PAPP-A and fβhCG, 39
secondary sonographic markers, 39–41, 40
second trimester screening, 41
sonographic detection
malformations, 41–2, 42
minor markers, 42–4, 43
nucleoside reverse transcriptase inhibitors
(NRTI), 241
NVP see nausea and vomiting during pregnancy
(NVP)
obesity
clinical significance, 157
complications, 160–161
diagnosis, 158, 158–9
interpregnancy weight loss, 162
lifestyle modifications, 162
pathophysiological changes, 161
pathophysiology, 157–8
prenatal visit, 159–60
treatment, 159
oligohydramnios, 315
amniinfusion, 322–3
during delivery, 322
diagnosis, 317–19, 320
evaluation, 319–21
fetal growth and placental function, 321
fetal urinary tract anatomy and function, 321
maternal hydration, 323
pulmonary hypoplasia, 321–2
oral iron, 85
ovarian cysts, 266
overt hypothyroidism, 174
oxytocin, 337, 416, 416, 468
pancreatic disease
clinical significance, 271, 271
complications, 276
diagnosis, 273–4
pathophysiology, 272
treatment, 275–6
parvovirus B19 infection
diagnosis, 246–7
epidemiology, 246
fifth disease, 247–8
management, 248–9
pathophysiology, 245–6
pelvic inflammatory disease, 268
peripartum cardiomyopathy
clinical significance, 139
complications, 140–141
diagnosis, 140
eliopathogenesis, 139–40
management, 140
patient follow up, 141
prevention, 141
persistent asthma, 189, 190, 192
placenta accreta
antepartum obstetric care, 439–40
clinical significance, 435
complications, 438
conservative management, 442–3
diagnosis, 436–8
pathophysiology and risk factors, 435–6
patient follow up, 443
placenta previa, 399, 401, 404
prevention, 443
prior cesareans, 399, 401, 404
surgical
suspected accreta, 440–1
unsuspected accreta, 441–2
Pneumocystis carinii prophylaxis (PCP), 241
polyhydramnios
amniocentesis, 325
amnioreduction, 326–7
biophysical monitoring, 327
complications, 325
diagnosis, 324–5
fetal growth restriction, 73
indomethacin, 327
laboratory screening, 325
labor management, 326
pathological accumulation, 323
preterm labor, cervical length for, 326
sonography, 325
treatment options, 326
postpartum hemorrhage
clinical significance, 462
complications, 468
diagnosis, 464, 464
pathophysiology, 462–3, 463
patient follow up, 468
prevention, 468
treatment
conservative surgical procedures, 465, 467
massive transfusion protocol, 465
selective arterial embolization, 467
uterine atony, 467
volume resuscitation, 465
preeclampsia
complications, 338
diagnosis
edema, 331
gestational hypertension, 331
proteinuria, 331
severe features, 332
severe hypertension, 331
follow up and maternal counseling, 338
management
mild hypertension, 332–4, 333
severe features, 334, 334–8
pathophysiology, 329–30, 330
rate of, 329
Index

pregestational diabetes mellitus
antepartum care, 164–5
delivery, 165–6, 166
fetal evaluation, 165
malformations, detection and evaluation of, 164
prepregnancy care, 164
risk assessment, 164
pregnancy-unique quantification of emesis and nausea (PUQE), 300
premature rupture of the membranes (PROM)
cervical cerclage, 379–80
clinical implications, 370–371
diagnosis, 371–2
evaluation, 372–3
herpes simplex virus, 380
human immunodeficiency virus, 380
management
conservative, 373
prior to 23 weeks, 378–9
23–31 weeks, 375–8
32–33 weeks, 374–5
34–36 weeks, 374
37 weeks/more, 374
membranes, resealing of, 380
pathophysiology, 369, 370
prevention, 380–381
preterm birth
clinical significance, 383
complications, 385–6
diagnosis, 384, 385
follow up and prevention, 386
management, 384–5, 385
pathophysiology, 383
preterm labor, 364
clinical significance, 363
complications, 365, 367
diagnosis, 363–4
follow up, 367
pathophysiology, 363
prevention, 367, 368, 368

treatment, 365, 365–6
preterm premature rupture of membranes (PPROM), 254, 257 see also amnionitis PROM see premature rupture of the membranes (PROM)
propylthiouracil (PTU), 176, 177, 300
prostaglandin E₁, 52, 378, 414, 467
prostaglandin E₂, 415, 467
proteinuria, 151, 204, 331, 336
pulsed-wave Doppler velocimetry, 54, 58, 59, 346
purified protein derivative (PPD) skin test, 228, 229

RA see rheumatoid arthritis (RA)
recombinant immunoblot assay (RIBA), 182
red cell distribution width (RDW), 82
renal disease
anemia, 155
dialysis, 155
dietary consultation, 154–5
effects and outcome, 152
fetal outcome, 152–3
fetal surveillance, 154
incidence, 150
maternal morbidity, 150
perinatal outcome, 151
physiological changes, 150
prepregnancy counseling, 153
renal biopsy, 155
renal ultrasonography, 154
REPROTOX, 9
reticuloendothelial system (RES), 97
rhesus immune globulin (RhIG), 361, 361
rheumatoid arthritis (RA)
diagnosis, 110–111
management, 111
pathophysiology, 110
pregnancy, effect of, 111
prevalence, 110
ribavirin, 184
rubella
diagnosis, 216–17
management, 217
scleroderma (SS)
effect of pregnancy on, 112–13
effect on pregnancy, 113
management, 113
pathophysiology, 112
stillbirth and preterm delivery, 112
Sheehan syndrome, 404
Shirodkar cerclage, 293
shoulder dystocia
management, 446–8
abdominal rescue, 449
cephalic replacement (Zavanelli maneuver), 448
documentation, 449
extraordinary maneuvers, 448
Gaskin maneuver, 448
symphysiotomy, 449
pathophysiology and diagnosis, 445–6, 446
sickle cell disease
B19 infection, 245
clinical significance, 88–9
complications, 91–2
diagnosis, 90
management protocol
antepartum (inpatient), 94–5
antepartum ( outpatient), 93–4
intrapartum, 95
postpartum, 95
pathophysiology, 89
patient follow up, 92–3
sickle cell trait, 95–6
transfusions, 90–91
VTE, 122
Index

491

SLE see systemic lupus erythematosus (SLE)

small-for-gestational-age (SGA), 206

smoking cessation, 343–4

counseling session, 4
e-cigarettes, 6
intervention, 5
pharmaceutical cessation aids, 5
varenicline, 6

Streptococcus agalactiae see group B streptococcus (GBS)

superimposed preeclampsia, 107, 153, 155, 203–4

symphysiotomy, 425, 449

syphilis

congenital syphilis, 217
diagnosis, 217–18
management, 218–19
prevalence, 217

systemic lupus erythematosus (SLE)
antepartum SLE flare, 108–110
diagnosis, 104–5, 105
effects, on pregnancy, 105–6
evaluation, 106–7, 107
pathophysiology, 104
prevalence, 104
treatment, 107–8

TB see tuberculosis (TB)
third trimester bleeding

complications, 404

diagnosis, 400–402
management, 402–4
pathophysiology, 398–400
thromboembolism

anticoagulant prophylaxis, 148
artificial heart valves, 147
diagnosis, 144, 144–5
epidural anesthesia, 148
pathophysiology, 143
prevention, 147
treatment of, 145–7, 146

thyroid cancer, 174
thyroid disorders
diagnosis of, 172–3, 173
hyperthyroidism
etiologies, 175
implications for, 175–6
management, 176–8
hypothyroidism

Hashimoto thyroiditis, 173
implications for, 174
iodine deficiency, 174
treatment, 174–5
thyroid-stimulating hormone (TSH), 172, 173
thyroid-stimulating immunoglobulins (TSI), 173, 175
thyroid storm, 176, 178
tobacco
clinical significance, 3–4
complications, 6–7
follow up and prevention, 7
pathophysiology, 4
smoking cessation
counseling session, 4
e-cigarettes, 6
intervention, 5
pharmaceutical cessation aids, 5
varenicline, 6
tocolysis, 366, 377, 455
toxoplasmosis
diagnosis, 219–20
treatment, 220
transcerebellar diameter (TCD), 343
trial of labor after cesarean delivery (TOLAC)
clinical judgment, 430
contraindications, 431, 432
indication, 429
patient counseling, 429

trimethoprim-sulfamethoxazole (TMP-SMZ), 241
tuberculosis (TB)
complications, 230
diagnosis, 228–9, 229, 229
pathophysiology, 228
treatment, 229–30
twin pregnancies, 452, 454, 477
twin–twin transfusion syndrome, 477

urinary calculi, 267
urinary tract infection, 266
uterine leiomyomata, 267
uterine rupture
diagnosis, 433
management, 433
risk factors, 432–3

vaginal birth after cesarean (VBAC)
prelabor counseling, 428–30, 429
TOLAC, 430–1

vaginal bleeding
clinical significance, 281
diagnosis and treatment, 282
early pregnancy loss, 283–4, 284
ectopic pregnancy, 284–5
follow up after pregnancy loss, 286
intrauterine pregnancy, 282–3
location, 285
molar pregnancy, 286
pathophysiology, 281–2
vancomycin, 95, 254, 258
Vaqta®, 185
varicella-zoster virus (VZV)
complications, 227
diagnosis, 226
pathophysiology, 226
prevention, 227
treatment, 227
### 492 Index

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>vasa previa</td>
<td>398, 400–403</td>
</tr>
<tr>
<td>VBAC (vaginal birth after cesarean)</td>
<td>VBAC</td>
</tr>
<tr>
<td>venous plasma glucose</td>
<td>170, 171</td>
</tr>
<tr>
<td>venous thromboembolism (VTE)</td>
<td>115</td>
</tr>
<tr>
<td>risk of</td>
<td>121</td>
</tr>
<tr>
<td>warfarin</td>
<td>146</td>
</tr>
<tr>
<td>Vibroacoustic stimulation (VAS)</td>
<td>65, 67, 419</td>
</tr>
<tr>
<td>viral hepatitis</td>
<td>180, 267</td>
</tr>
<tr>
<td>VZV (varicella-zoster virus)</td>
<td>VZV</td>
</tr>
<tr>
<td>warfarin</td>
<td>118, 134, 146, 479</td>
</tr>
<tr>
<td>West Nile virus</td>
<td></td>
</tr>
<tr>
<td>complications</td>
<td>225–6</td>
</tr>
<tr>
<td>diagnosis</td>
<td>225</td>
</tr>
<tr>
<td>pathophysiology</td>
<td>225</td>
</tr>
<tr>
<td>prevention</td>
<td>226</td>
</tr>
<tr>
<td>treatment</td>
<td>225</td>
</tr>
<tr>
<td>Zavanelli maneuver</td>
<td>448</td>
</tr>
</tbody>
</table>